FEB 01, 2021
AAO 2020 Virtual
Ocular Pathology/Oncology, Uveal Tract
In this video from AAO 2020 Virtual, Dr. Carol Shields discusses findings from a light-activated treatment for choroidal melanoma. The nanoparticle (AU-011) is attached to a chromophore that binds to melanoma cells and is activated by 689 nm light. Earlier trials showed that intravitreal delivery of the particle look promising; investigators are now exploring the efficacy of suprachoroidal delivery of AU-011.
To learn more, watch Dr. Shield's talk, “AU-011, a Targeted Therapy for Primary Treatment of Choroidal Melanoma (CM) via Intravitreal (IVT) and Suprachoroidal (SC) Administration,” during the session “Late Breaking Developments, Part I" (RET10V).
Relevant financial disclosures: Dr. Shields is a consultant for Aura Biosciences.